Big data – what’s in it for the patient?
03 Nov 2016
The hardest thing in medicine is to distinguish normal from abnormal. Aggregated, standardised, ‘big’ data can help us achieve this – we will look at examples using liver disease assessed by MRI as a paradigm.
Educational aims/learning objectives:
• Use of quantitative MRI in research and daily clinical practice for rare and chronic disease
• Imaging and genetics – cornerstones of 21st century diagnostics
References and citations:
• Pavlides et al, Journal of Hepatology 2016
• Banerjee et al, Journal of Hepatology 2014
0.5 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
Educational aims/learning objectives:
• Use of quantitative MRI in research and daily clinical practice for rare and chronic disease
• Imaging and genetics – cornerstones of 21st century diagnostics
References and citations:
• Pavlides et al, Journal of Hepatology 2016
• Banerjee et al, Journal of Hepatology 2014
0.5 CPD credit.
Watch the video and complete the online self-reflection form. Go to "My events" to download your certificate. You must login to watch the video and receive CPD.
Duration:26 mins
Speaker info
Rajarshi Banerjee
Dr Rajarshi Banerjee is CEO of Perspectum Diagnostics and a Consultant Physician in Oxford. He graduated in 2002 before moving to London as a specialist registrar in general medicine and cardiology. He was awarded a BHF Clinical Research Training Fellowship in 2008 to study the pathophysiology of obesity in Oxford. Working with techniques developed in and patented by the Oxford Centre for Clinical Magnetic Resonance (OCMR), his Rapid Imaging in Liver Disease (RIAL) study used liver biopsy as a reference to show that quantitative MR enabled radiologists to diagnose and stage liver disease. Quantitative MR had high diagnostic accuracy for each of liver fat, fibrosis and iron content, and could predict clinical outcomes. This led to the formation of the spinout Perspectum Diagnostics, and its first product, LiverMultiScan, which gained FDA clearance in 2015. Rajarshi continues to work in translational medicine with patient-based clinical studies.